摘要
目的探讨肝动脉灌注栓塞(TACE)治疗原发性肝癌的临床疗效。方法方便选取2012年1月—2016年12月该院收治的102例原发性肝癌患者为研究对象,依据治疗方式不同将入选病例分为实验组(TACE+支持治疗,51例)和对照组(支持治疗,51例)。对比观察两组近期治疗有效率、瘤体控制率及远期生存率。结果实验组近期治疗有效率35.29%,瘤体控制率72.55%,1年生存率66.67%,3年生存率35.29%,平均生存时间(11.2±1.6)个月,各项指标均优于对照组,比较差异有统计学意义(P<0.05)。结论肝动脉灌注栓塞治疗原发性肝癌效果良好,尤其适用于直径小、有包膜且血运丰富的病灶,有助于延长患者生存期,值得临床推广使用。
Objective To study the clinical curative effect of transhepatic arterial infusion embolization in treatment of patients with primary liver cancer. Methods 102 cases of patients with primary liver cancer admitted and treated in our hospital from January 2012 to December 2016 were convenient selected and divided into two groups with 51 cases in each, the experimental group adopted the TACE and support treatment, while the control group adopted the support treatment, and the treatment effective rate, tumor body control rate and long-term survival rate of the two groups were compared and observed.Results The short-term treatment effective rate, tumor body control rate, 1-year survival rate, 3-year survival rate, average survival time in the experimental group were respectively 35.29%, 72.55%, 66.67%, 35.29%（11.2±1.6）months, and the differences between groups were statistically significant（P〈0.05）. Conclusion The effect of transhepatic arterial infusion embolization in treatment of patients with primary liver cancer is good, especially for the lesions with small diameter and rich blood transportation, and it contributes to prolonging the survival period of patients, and it is worth clinical promotion and application.
出处
《中外医疗》
2017年第18期128-129,132,共3页
China & Foreign Medical Treatment
关键词
原发性肝癌
肝动脉灌注栓塞
临床疗效
Primary liver cancer
Transhepatic arterial infusion embolization
Clinical curative effect
